Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | 5-ARIs: impacts on prostate volume and PSA

James Kearns, MD, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the use of 5-alpha-reductase inhibitors (5-ARIs), which prevent the conversion of testosterone to dihydrotestosterone, to treat benign prostatic hyperplasia and male pattern hair loss. 5-ARIs can cause a 25-30% reduction in prostate volume with the intention of relieving bladder outlet obstruction. After 6 months of 5-ARI therapy, prostate-specific antigen (PSA) levels can decline by roughly 50%. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.